Abstract Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions
through an anchored transmembrane molecule and a soluble circulating protein. Both …

Introduction Obesity is recognized as a major healthcare challenge. Following years of slow
progress in discovery of safe, effective therapies for weight management, recent approval of …

OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …

When glucose is taken orally, insulin secretion is stimulated much more than it is when
glucose is infused intravenously so as to result in similar glucose concentrations. This effect …

Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a membrane-anchored cell
surface peptidase that transmits intracellular signals via a short intracellular tail and as a …

Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins, glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The first …

Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential …

Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type
2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body …

ABSTRACT Background: Glucagon-like peptide-1 (GLP‑1) and glucose-dependent
insulinotropic polypeptide (GIP) are hormones secreted by the enteroendocrine cells of the …

The introduction of dipeptidyl peptidase 4 (DPP4) inhibitors for the treatment of Type 2
diabetes acknowledges the fundamental importance of incretin hormones in the regulation …